ReviewNeuroscience bulletin2026
The Role of Serotonergic System in Parkinson's Disease-Related Pain.
Review in Neuroscience bulletin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pain affects up to 85% of Parkinson's disease (PD) patients, but treatment options remain limited. The brainstem serotonergic raphe nuclei, as the main source of central serotonin, dysfunction early in PD. Serotonin mediates descending pain inhibition to the spinal cord, and disruption of this pathway likely increases pain susceptibility. Concurrently, serotonergic projections to supraspinal regions shape the emotional-affective dimension of pain, which may explain why mood disturbances and pain often co-occur in PD. Clinically, selective serotonin reuptake inhibitors (SSRIs) and other serotonin-targeting drugs show efficacy in both PD depression and chronic pain conditions. This review synthesizes current evidence on serotonergic mechanisms in PD pain and identifies potential therapeutic targets, thereby providing a foundation for mechanism-based treatment strategies.
Indexed as
Identifiers
42274907What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.